Leading Digital Healthcare: The Pharmaceutical Industry's GEA Strategy Launch, Opening a New Paradigm for Pharmaceutical Academic Operations with System Capabilities | Tezign x unimind

Introduction: At a critical moment when the pharmaceutical industry officially shifts from "relationship-driven" to "professional-driven," Tezign Technology, based on its strategic cooperation with Weitong Yizhe, launched the GEA system for the pharmaceutical industry. This is not an upgrade of a marketing tool, but a systematic reconstruction of the academic operation methods of pharmaceutical companies—from isolated academic activities to a continuously operating medical knowledge system; from merely pursuing dissemination efficiency to balancing professional depth and long-term value accumulation; from project-based thinking to system-based capabilities.

On May 21, Tezign Technology and leading digital healthcare company Weitong Yizhe held a closed-door industry seminar in Shanghai. At the meeting, both parties announced a strategic partnership and launched the GEA system for the pharmaceutical industry for the first time.

The implementation of the "Management Measures for Pharmaceutical Representatives" and the introduction of the "Criminal Law Amendment (12)" have changed the fundamental logic of competition in the pharmaceutical industry. When industry competition shifts from "relationship-oriented" to "professional-oriented," pharmaceutical companies face a real paradox: emphasizing medical depth can easily lead to a lack of dissemination power, while pursuing efficiency can easily touch regulatory red lines.

Single, fragmented AI tools cannot simultaneously meet the three dimensions of "professionalism," "efficiency," and "compliance." What the industry needs is an enterprise-level solution that understands medical logic, possesses systematic thinking, and can continuously accumulate and generate value from academic assets.

The Pharmaceutical GEA integrates a system architecture that eliminates the opposition between these two aspects.

Solving the Pharmaceutical Marketing Paradox of “Professionalism” and “Efficiency”

The Pharmaceutical GEA adopts a four-layer architecture of enterprise-level intelligence, deeply customized for the pharmaceutical industry.

Starting from business intent, the system transforms it into a structured execution path, intelligently orchestrating over 150 specialized capability modules in the pharmaceutical field through a reasoning engine that integrates multiple constraints such as medical evidence standards, regulatory compliance requirements, and brand positions, while making decisions based on the enterprise's complete medical knowledge system. This enables the Pharmaceutical GEA to find the optimal path that is both professional and effective amidst seemingly contradictory multiple demands, continuously optimizing the enterprise's academic operation system through ongoing learning and feedback.

Based on the enterprise-built medical professional knowledge base and context management system, GEA consolidates brand assets, clinical data, professional norms, and compliance requirements into structured medical knowledge that can be continuously accessed.

On this basis, combined with regulatory policy constraints and market insights, it conducts multi-dimensional reasoning and transformation, ensuring that each content generation is derived from the enterprise's professional accumulation rather than generalized understanding of common models, automatically generating corresponding content versions based on the needs of different audiences and channels—the doctor version reflects evidence-based medicine standards (GRADE system), the patient version pursues ease of understanding and accuracy, and the social version balances fun and professionalism. These versions all originate from the same medical source but achieve optimal effects in their respective dissemination environments.

At the same time, the built-in multi-layer compliance mechanism conducts evidence level verification, regulatory policy compliance checks, and brand position consistency checks at every stage of content generation. The enterprise's marketing efforts are no longer a passive response to risks but are proactively conducted based on a full understanding of the constraints.

From content generation to publication, built-in evidence level verification, regulatory compliance checks, and brand position checks ensure that enterprises proactively understand constraints rather than passively respond to risks. Pharmaceutical companies no longer have to choose between "professionalism" and "dissemination power," nor do they passively respond to compliance issues afterward; instead, they actively operate academic marketing based on a full understanding of all constraints.

Six Application Scenarios: End-to-End Operations from Academic Conferences to Patient Education

The Pharmaceutical GEA has demonstrated strong execution in practice. The following six scenarios cover the entire chain of pharmaceutical marketing, each directly addressing the real business pain points of professionalism, efficiency, and compliance:

1. HCP Academic Content Operation System

Based on doctors' professional backgrounds, academic interests, and treatment preferences, the system continuously generates personalized medical content. Doctors receive not a one-time push but a long-term updated professional learning system.

2. Matrix Content for Multiple Uses

A core medical viewpoint is automatically broken down into: medical reports, short video scripts, social media materials, conference speeches, and patient education materials. This allows the company's medical investments to achieve multiple returns.

3. Real-Time Transformation of Academic Conferences

Expert opinions and discussion summaries at the conference site are captured and structured in real-time, automatically generating meeting summaries, attendance guides, and follow-up educational materials, extending the academic value of a conference from "3 months" to "one year."

4. Precise Generation of Medical Visit Materials

Based on doctors' needs, local medical environments, product indications, and other information, the most persuasive visit materials are automatically generated—ensuring both the rigor of evidence-based medicine and the targeting of sales arguments, significantly improving the conversion rate of medical visits.

5. Full Process Compliance Mechanism for Content Generation

Each piece of content undergoes three "compliance checks": evidence level verification (GRADE system) → regulatory policy compliance check → brand position consistency check. Enterprises shift from passively responding to risks to proactively understanding constraints.

6. Generative Search Engine Optimization (GEO)

Generative search engines become a new entry point for information, transforming complex medical content into expressions that are easy for AI engines to understand and reference, allowing pharmaceutical companies' academic achievements to gain higher exposure in the new era of search.

Tezign Technology is a leading enterprise-level intelligence company in China and one of Shanghai's key artificial intelligence enterprises under the "Big Dipper" initiative. Tezign helps enterprises achieve growth, innovation, and productivity improvement through its self-developed enterprise-level intelligence system (GEA, Generative Enterprise Agent).

Weitong Yizhe Health Technology is a leading digital service enterprise in the healthcare field, with deep industry experience in evidence-based medical communication, pharmaceutical digital marketing, and patient health education.

This collaboration combines Tezign's enterprise-level AI technology advantages with Weitong Yizhe's deep experience in medical communication, providing pharmaceutical companies with a comprehensive solution that balances dissemination efficiency and professional quality.

From a broader perspective, when pharmaceutical companies have a continuously operating, complete medical knowledge system, the way they compete fundamentally changes—companies no longer rely on control over doctors or channels but on a deep understanding of the medical system and systematic operational capabilities. This capability is more in line with the new regulatory environment and is more sustainable.

From "single-point tools" to "system solutions," the future competition of pharmaceutical companies will unfold on the track of "continuous construction and optimization of a complete academic system."

If you are interested in learning more, feel free to scan the code to obtain more practices or submit your pain points, and engage in dialogue with our pharmaceutical industry FDE experts for in-depth diagnosis.